Importantly, in mouse syngeneic models that respond poorly to mAbs targeting either PD-L1 or CTLA-4, combination with MEDI9197 significantly improved anti-tumor activity when compared to either monotherapy alone. The gene discussed is CD274; the disease is neoplasm.